GDTC: w2.cytomed.sg Kompaniya qiymatining sof foydaga nisbati
CytoMed Therapeutics (GDTC) robotlashtirilgan birikmalar skriningi orqali klinikadan oldingi sinovlarni tezlashtirmoqda, bu esa NK-hujayralarining yashab qolishi va Singapurda ishlab chiqarishni kengaytirish uchun juda muhimdir. GURU.Markets platformasida separate_pe metriki bo'yicha bozor narxi hozirda -3.70 darajasida turibdi. Singapurda joylashgan hujayra terapiyasi ishlab chiquvchisi hali daromadli emas, buning o'rniga o'z dori vositalarini bozorga chiqarish uchun joriy testlarning muvaffaqiyati va kelgusidagi tartibga soluvchi tasdiqlarga tayanmoqda.
%20P%2FE%20multiplikatori&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_GDTC_-_CytoMed-Therapeutics_-_PE-Multiple "GDTC: CytoMed Therapeutics Narx-foyda koeffitsiyenti 21.02.2024 - 12.11.2026 | 👁️GURU.Markets👁️")
CytoMed Therapeutics Ltd (GDTC) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil
- aksiya kursi va ekspertlarning narx prognozi:
- bozor kapitallashuvi haqida ma'lumot:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Barcha qarzlarning o‘z mablag‘lariga nisbati CytoMed Therapeutics|GDTC - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati CytoMed|GDTC - Kompaniyaning jamlangan qarzlari|Qarzning balans qiymatiga nisbati CytoMed Therapeutics Limited|GDTC - Kompaniyaning uzoq muddatli majburiyatlari|Qisqa muddatli qarz CytoMed Therapeutics|Oraliq likvidlik koeffitsiyenti w2.cytomed.sg
- kompaniyaning daromadliligi va baholash multiplikatorlari ko'rsatkichlari:
GDTC - Kompaniyaning sof foydasi|Kutilayotgan sof foyda CytoMed Therapeutics|GDTC - Narxning foydaga nisbati|Prognoz qilingan narxning foydaga nisbati CytoMed|GDTC - PEG multiplikatori|Kompaniya qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati CytoMed Therapeutics Limited|GDTC - EBITDA operatsion foydasi|So'nggi 12 oy davomida bir aksiya uchun foyda CytoMed Therapeutics|GDTC - So'nggi 12 oy davomida bir aksiya uchun sof foyda|So'nggi 12 oy davomida bitta aksiya uchun foydaning yillik o'sishi w2.cytomed.sg|GDTC - Bu yil bir aksiya uchun sof foyda o'sishi|Keyingi yilda bir aksiya uchun foydaning prognoz qilingan ortishi CytoMed Therapeutics
Kompaniyaning jamlanma tahlili:GDTC w2.cytomed.sg
CytoMed Therapeutics (GDTC) kompaniyasiga nisbatan bozor kutganlari, T-hujayra terapiyalarini ishlab chiqishning yuqori xarajatlari va FDA ning qat'iy nazorati tufayli ko'pincha joriy daromadlardan oshib ketadi. Kompaniyaning yillik P/E koeffitsiyentini tahlil qilish orqali investor bozor kapitalizatsiyasi va sof foyda o'rtasidagi bog'liqlikni baholaydi, bu esa eksklyuziv patentlar uchun to'langan premiumni va biznesning Osiyodagi lobbi salohiyatini aniqlashga yordam beradi.
Raqobatdosh kompaniyalar
ONC: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti HALO (Halozyme)|RVMD (Revolution Medicines Inc) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori AAPG (Ascentage)|CGON - Narx-foyda koeffitsiyenti|URGN: Narx-foyda koeffitsiyenti|BCAX - P/E multiplikatori|Personalis (PSNL) - Narxning foydaga nisbati|Erasca Inc - Kompaniya qiymatining sof foydaga nisbati|DCTH (Delcath) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Y-mAbs Corp YMAB|P/E multiplikatori AURA|Narx-foyda koeffitsiyenti candeltx.com CADL|Accuray - Narx-foyda koeffitsiyenti|SELLAS Life Sciences Group, Inc. (SLS) - Kapitalizatsiyaning foydaga nisbati|ACTU: Narx-foyda koeffitsiyenti|Citius Oncology Inc - Bozor narxining sof foydaga nisbati|tuhurabio.com (HURA) - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati protaratx.com (TARA)|Narxning foydaga nisbati Fate Therapeutics|Narx-foyda koeffitsiyenti Aadi Bio (WHWK)|P/E multiplikatori TCRX|CSBR - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori XBIT (XBiotech)|CVM: Narx-foyda multiplikatori|OSTX: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati RADX (radiopharmtheranostics.com)|ARTV (artivabio.com) - Narx-foyda koeffitsiyenti|ANL: Bozor narxining sof foydaga nisbati|VERU (Veru Inc.) - P/E multiplikatori|TPST: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori XLO|RENB - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati Mural Oncology MURA|Kompaniya qiymatining sof foydaga nisbati KAPA|OnKure - P/E multiplikatori|CRIS - P/E multiplikatori|apollomicsinc.com (APLM) - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati THAR (Tharimmune Inc)|ADVB (Advanced Biomed Inc.) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Genprex Inc GNPX|Narx-foyda koeffitsiyenti CLDI (Calidi Biotherapeutics)|P/E multiplikatori sunshinebiopharma.com (SBFM)|Xenetic Biosciences, Inc. - Narx-foyda koeffitsiyenti|Bozor narxining sof foydaga nisbati SLRX (Salarius Pharmaceuticals Inc)|Purple Biotech Corp - P/E multiplikatori|Biznesning o‘zini qoplash muddati American Oncology Network AONC|BGNE: P/E multiplikatori|Narx-foyda koeffitsiyenti checkpointtx.com|Narxning foydaga nisbati Elevation Oncology|iCAD Corp (ICAD) - Biznesning o‘zini qoplash muddati|P/E multiplikatori IKNA|Notable Labs Corp (NTBL) - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|P/E multiplikatori VIRX (Viracta Therapeutics, Inc.)|MOR: Narx-foyda multiplikatori|NAYA: Narx-foyda koeffitsiyenti|Ascentage Pharma Group International - Bozor narxining sof foydaga nisbati
